Department of Gynecology, Sapporo Medical University, Sapporo, Japan.
Department of Obstetrics and Gynecology, Steel Memorial Muroran Hospital, Muroran, Japan.
J Obstet Gynaecol Res. 2024 Oct;50(10):1801-1807. doi: 10.1111/jog.16082. Epub 2024 Sep 11.
The importance of human papillomavirus (HPV) co-testing using physician-, self-, and urine-collected samples to predict cervical intraepithelial neoplasia (CIN) grade 1-2 prognoses has not been previously reported. Therefore, this study aimed to investigate outcomes of patients with CIN 1-2 who simultaneously underwent physician-, self-, and urine-collection sampling tests.
This study was conducted in Japan between October 2019 and November 2022 and examined the proportion of cases with CIN 1-2 progressions, the percentage of cases with persistent CIN 1-2, and the outcome differences according to the results of physician-, self-, and urine-sampling tests.
There were 105 and 59 CIN 1 and 2 cases, respectively, with progression or persistence in 27 (29.3%) and 21 (50.0%) cases, respectively. The median follow-up was 20 and 12 months, respectively. Progression and persistence of CIN 1 were significantly associated with HPV-positive physician- and self-collected samples. No significant difference was observed between cases with CIN 2 who had HPV-positive and HPV-negative results using any sampling method.
Physician- and self-testing for HPV are crucial for predicting disease progression risk in CIN 1 cases. Future research with an extended observation period and consideration of the progression risks is warranted.
尚未有研究报道过使用医师采样、自我采样和尿液采集样本进行人乳头瘤病毒（HPV）联合检测对预测宫颈上皮内瘤变（CIN）1-2 级预后的重要性。因此，本研究旨在探讨同时接受医师采样、自我采样和尿液采集样本检测的 CIN 1-2 患者的结局。
本研究于 2019 年 10 月至 2022 年 11 月在日本进行，检查了 CIN 1-2 进展病例的比例、CIN 1-2 持续病例的百分比以及根据医师采样、自我采样和尿液采样检测结果的差异。
CIN 1 和 2 分别有 105 例和 59 例，进展或持续分别为 27 例（29.3%）和 21 例（50.0%）。中位随访时间分别为 20 个月和 12 个月。CIN 1 的进展和持续与 HPV 阳性的医师采样和自我采样样本显著相关。HPV 阳性和 HPV 阴性结果的 CIN 2 病例在任何采样方法中均无显著差异。
医师采样和自我检测 HPV 对于预测 CIN 1 病例的疾病进展风险至关重要。未来的研究需要延长观察期并考虑进展风险。
